Responders and super-responders to anti-CGRP mAbs: the large, prospective, multicenter, real-life, I-NEED study

被引：0

作者：

Egeo, G. ^{[1
]}

Aurilia, C. ^{[1
]}

Torelli, P. ^{[2
]}

Finocchi, C. ^{[3
]}

D'Onofrio, F. ^{[4
]}

Messina, S. ^{[5
]}

Colombo, B. ^{[6
]}

Aguggia, M. ^{[7
]}

Tasillo, M. ^{[8
]}

Filippi, M.

Fiorentini, G. ^{[9
]}

Orlando, B. ^{[1
]}

Proietti, S. ^{[10
]}

Bonassi, S. ^{[11
]}

Barbanti, P. ^{[1
]}

机构：

[1] IRCCS San Raffaele Rome, Headache & Pain Unit, Rome, Italy

[2] Univ Parma, Dept Med & Surg, Neurol Unit, Headache Ctr, Parma, Italy

[3] San Paolo Hosp, Neurol Unit, ASL 2, Savona, Italy

[4] San Giuseppe Moscati Hosp, Neurol Unit, Avellino, Italy

[5] IRCCS Ist Auxol Italiano, Dept Neurol Stroke Unit, Lab Neuroscience, Milan, Italy

[6] Univ Vita Salute San Raffaele, Sci Inst San Raffaele Hosp, Dept Neurol, Headache Unit, Milan, Italy

[7] Cardinal Massaia Hosp, Neurol & Stroke Unit, Asti, Italy

[8] S Camillo Lellis Hosp, Stroke Unit, Rieti, Italy

[9] San Raffaele Univ, Rome, Italy

[10] IRCCS San Raffaele Rome, Clin & Mol Epidemiol, Rome, Italy

[11] San Raffaele Univ, Dept Human Sci & Qual Life Promot, Rome, Italy

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPO-078

引用

页码：373 / 374

页数：2

共 23 条

[1] Reversion from CM to EM with anti- CGRP mAbs: a prospective, multicenter study on 1109 patients (the I-NEED study)
Egeo, G.
Aurilia, C.
Torelli, P.
Finocchi, C.
D'Onofrio, F.
D'Onofrio, L.
Di Clemente, L.
Ranioeri, A.
Zoroddu, F.
Frediani, F.
Fiorentini, G.
Orlando, B.
Proietti, S.
Bonassi, S.
Barbanti, P.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 150 - 150
[2] Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study
Cakmak, Mehmet Erdem
Oztop, Nida
Yegit, Osman Ozan
Ozdedeoglu, Oezlem
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, : 736 - 743
[3] Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year
Liu, Yizhang
Hu, Kun
Jian, Lu
Duan, Yongfang
Zhang, Mi
Kuang, Yehong
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[4] Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
Simona, Guerzoni
Carlo, Baraldi
Daria, Brovia
Michela, Cainazzo Maria
Flavia, Lo Castro
Luca, Pani
ACTA NEUROLOGICA BELGICA, 2023, 123 (03) : 1039 - 1047
[5] Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
Simona Guerzoni
Carlo Baraldi
Daria Brovia
Maria Michela Cainazzo
Flavia Lo Castro
Luca Pani
Acta Neurologica Belgica, 2023, 123 : 1039 - 1047
[6] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
Simona Guerzoni
Flavia Lo Castro
Daria Brovia
Carlo Baraldi
Luca Pani
Neurological Sciences, 2024, 45 : 1661 - 1668
[7] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
Guerzoni, Simona
Castro, Flavia Lo
Brovia, Daria
Baraldi, Carlo
Pani, Luca
NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1661 - 1668
[8] European multicenter study on the use of anti-CGRP monoclonal antibodies in real life for migraine prevention: study cohort description
Caronna, Edoardo
Jose Gallardo, Victor
Alpuente, Alicia
Torres-Ferrus, Marta
Huerta Villanueva, Mariano
Munoz, Albert
Campoy, Sergio
Cuadrado Godia, Elisa
Dorado, Laura
Obach, Victor
Fabregat, Neus
Rodriguez Vico, Jaime
Diaz de Teran, Javier
Membrilla, Javier
Pascual, Julio
Garate, Gabriel
Gago, Ana
Guerrero, Angel
Sanahuja, Jordi
Sanchez Soblechero, Antonio
Lozano Ros, Alberto
Irimia Sieira, Pablo
Sanchez del Rio, Margarita
Echeverria Urabayen, Amaya
Garcia Azorin, David
Gonzalez Osorio, Yesica
Gonzalez Quintanilla, Vicente
Lopez Bravo, Alba
Fernandez Lazaro, Iris
Quintas Gutierrez, Sonia
Gonzalez-Martinez, Alicia
Flores Pina, Belen
Manera Zorrilla-Lequerica, Paula
Jaimes Sanchez, Alex
Garcia Gomez, Andrea
Alvarez Escudero, Rocio
Oterino Duran, Agustin
Velasco Juanes, Fernando
Sifontes, Walter
Rodriguez Montolio, Joana
Nieves Castellanos, Candela
Olivier, Marina
Layos-Romero, Almudena
Andres Lopez, Alberto
Sanchez Caballero, Francisco
Beltran Blasco, Isabel
Millan Vazquez, Manuel
Lamas Perez, Raquel
Viguera Romero, Javier
Santos-Lasaosa, Sonia
CEPHALALGIA, 2023, 43 (1supp)
[9] Safety and tolerability of antiCGRP mAbs in real-life: a multicenter, prospective, observational study on 1635 migraine patients
Egeo, Gabriella
Aurilia, Cinzia
Orlando, Bianca
Fiorentini, Giulia
Torelli, Paola
Finocchi, Cinzia
d'Onofrio, Florindo
d'Onofrio, Luigi
Messina, Stefano
Zucco, Maurizio
Colombo, Bruno
Ranieri, Angelo
Salerno, Antonio
Petolicchio, Barbara
Valenza, Alessandro
Rinalduzzi, Steno
Zoroddu, Francesco
Camarda, Cecilia
Borrello, Laura
Albanese, Maria
Tomino, Carlo
Proietti, Stefania
Bonassi, Stefano
Barbanti, Piero
CEPHALALGIA, 2023, 43 (1supp) : 240 - 241
[10] Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study
Gantenbein, Andreas R.
Agosti, Reto
Gobbi, Claudio
Flugel, Dominique
Schankin, Christoph J.
Viceic, Dragana
Zecca, Chiara
Pohl, Heiko
CEPHALALGIA, 2021, 41 (11-12) : 1181 - 1186

← 1 2 3 →